Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant Protein-based Vaccine Against SARS-CoV-2, in a Population of Adult Volunteers Previously Vaccinated Against SARS-CoV-2 Virus.

NCT05752201 is registered in ClinicalTrials.gov with Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno as lead sponsor.

NCT NCT05752201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05752201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant Protein-based Vaccine Against SARS-CoV-2, in a Population of Adult Volunteers Previously Vaccinated Against SARS-CoV-2 Virus.
Lead sponsor
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Phase
Phase 2/3
Overall status
Completed
Start date
February 6, 2023
Completion date
December 7, 2023
Enrollment
2,014 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccine